Description
Sotalol is a non-selective inhibitor of β-adrenergic receptors that also inhibits Na+ and K+ channels. Sotalol acts as a class III anti-arrhythmic drug that also exhibits anti-fibrillatory activity. Sotalol is used clinically to treat ventricular fibrillation and ventricular tachycardia. In vitro and in vivo, sotalol prolongs action potential duration, QT and PR intervals, and increases the effective refractory period.
References
Burashnikov A, Pourrier M, Gibson JK, et al. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Circ Arrhythm Electrophysiol. 2012 Apr;5(2):400-8. PMID: 22322366.
Shah SA, Kluger J, White CM. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes. Pharmacotherapy. 2007 Sep;27(9):1297-305. PMID: 17723083.
Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005 May 5;352(18):1861-72. PMID: 15872201.
Boriani G, Lubinski A, Capucci A, et al. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J. 2001 Dec;22(23):2180-91. PMID: 11913480.
Touboul P, Atallah G, Kirkorian G, et al. Clinical electrophysiology of intravenous sotalol, a beta-blocking drug with class III antiarrhythmic properties. Am Heart J. 1984 May;107(5 Pt 1):888-95. PMID: 6720518.
Giudicelli JF, Lhoste F, Boissier JR. Beta-adrenergic blockade and atrio--ventricular conduction impairment. Eur J Pharmacol. 1975 Apr;31(2):216-25. PMID: 238853.